Dr Martens' US turnaround could see shares recover, says Edison

Following a recent "teach-in" day with the company last week, Edison hailed Dr Martens' ongoing product innovation, as well as its brand awareness and relevance among younger demographics through its collaborations with influencers and marketing campaigns on social media.

"DOCS’ consumer base is very diverse as well as loyal, with the brand consistently above peers for sentiment scores among UK consumers, which continues to be a driver for the group’s global growth prospects," said Russell Pointon, director of the consumer division at Edison.

The company also presented its sustainability strategy as it looks to target natural materials from regenerative agriculture by 2040 and removing fossil-fuel chemicals by 2035.

The shares are currently trading around the 140-150p level, not far off the record low of 113p reached in the summer after full-year results revealed that its North American performance was holding back group sales growth.

The company admitted at the time that it had made "operational mistakes" in the US, such as the move of a distribution centre and the execution of marketing campaigns and online trading. Management called the strategic review and turnaround of the regional business its "number one operational priority".

"DOCS currently trades on discounts of 48% and 32% for EV/EBITDA and P/E, respectively, in FY24 to global luxury, global footwear and sportswear brands. A weak share price performance since IPO in early 2021 due to a combination of operational issues and wider market effects means its valuation, naturally, looks low relative to its historical trading multiples," Pointon said.

He said that this valuation discount to the wider sector could "narrow" based on the performance in North America.

The stock was up 0.4% at 144.44p on Friday.